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PLEIOTROPHIN SIGNALING IS NECESSARY FOR HEMATOPOIETIC STEM
CELL SELF RENEWAL AND IS REGULATED BY THE BONE MARROW
MICROENVIRONMENT
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We recently demonstrated that treatment of murine and human
HSCs with the heparin binding growth factor, pleiotrophin
(PTN), was sufficient to induce self-renewal of murine and human
HSCs in culture (Himburg, Nat Med, 2010). In order to determine
if PTN signaling is necessary for HSC self renewal and normal he-
matopoiesis in vivo, we examinedmice bearing a constitutive deletion
of PTN (PTN 2/2 mice) (Jackson Laboratory). PTN 2/2 mice
demonstrated no significant differences in total bone marrow (BM)
cells or BM colony forming cells (CFCs), but had significantly
decreased bone marrow CD34(-)c-kit(1)sca-1(1)lin(-) (34-KSL)
cells (0.007% vs. 0.02%, p 5 0.03) and 2–fold decreased CFU-S12
content compared to control mice that retained PTN (PTN 1/1
mice)(p 5 0.003). Importantly, PTN 2/2 mice demonstrated an
11-fold decrease in long-term repopulating HSC content compared
to PTN 1/1 mice as measured by competitive repopulating unit
(CRU) assay (12 week CRU frequency: 1 in 6 cells vs. 1 in 66 cells).
To determine whether the effect of PTN deletion on HSC content
was cell autonomous, we generated chimeric mice by transplantation
of CD45.1 congenic BM cells into lethally irradiated CD45.2
PTN2/2 or PTN1/1 mice. After 8 weeks of transplantation, the
number of BM 34-KSLs and BM CFU-S content were significantly
decreased in the recipient PTN2/2 compared to the PTN1/1
mice (p5 0.04). These data demonstrated that the bone marrow mi-
croenvironment is necessary for PTN signaling with HSCs. By
quantitative real time PCR, we found that both BM osteoblasts
and endothelial cells in wild type mice express PTN. In addition,
treatment of non contact cultures of BM KSL cells and primary
BM ECs with anti-PTN blocked the capacity of BM ECs to support
the expansion of CFC and CFU-S in vitro compared to BM EC cul-
tures treated with isotype antibody (p5 0.01 and p\0.0001, respec-
tively). These data demonstrate that PTN is produced by BMECs in
the HSC niche and PTN signaling is necessary for maintenance of
the BM HSC pool in vivo.2
MANIPULATION OF THE BIOENERGETICS OF ALLOREACTIVE T CELLS
LEADS TO THEIR SELECTIVE APOPTOSIS AND ARRESTS GRAFT VERSUS
HOST DISEASE
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Ann Arbor, MI; 2The University of Florida, Gainesville, FL
Proliferating cells fuel division by increasing ATP production
through oxidative phosphorylation (OXPHOS) or glycolysis. Fol-
lowing bone marrow transplantation (BMT), both hematopoietic
stem cells (HSCs) and alloreactive T cells rapidly proliferate to re-
constitute the immune system or mediate graft versus host disease
(GVHD), respectively. Proliferating HSCs and progenitor cells on
d 8 after syngeneic BMT (B6/B6-Ly5.2) increased glycolysis 3-
fold (p\ 0.0001, Table 1) but did not increase OXPHOS. By con-
trast, alloreactive donor T cells in a B6/B6D2F1 model of
GVHD more than doubled OXPHOS compared to unstimulated
T cells (p \ 0.0001, Table 1), which accounted for 80-90% of
ATP produced. These results are surpising, as lymphocytes stimu-
lated in vitro generate ATP primarily through glycolysis. Alloreac-
tive donor T cells also proliferated twice as fast as proliferating
bone marrow cells (p\0.0001, Table 1). The more rapid prolifera-
tion and increased OXPHOS in alloreactive donor T cells was asso-
ciated with increased oxidative stress, as indicated by increased
reactive oxygen species (ROS), and a loss of the antioxidants pyruvate(98%decrease, p5 0.004) and glutathione (25% decrease, p5 0.04).
Proliferating bone marrow cells did not exhibit this abnormal bioen-
ergetic phenotype (Table 1).We exploited these redox abnormalities
using Bz-423, a novel benzodiazepine that modulates the mitochon-
drial F1Fo-ATPase and induces ROS-mediated apoptosis. One
injection of Bz-423 increased ROS production 2-fold in alloreactive
donor T cells (p\0.001), and increased their apoptosis by 50% (p\
0.001). Bz-423 did not produce ROS or induce apoptosis in unsti-
mualted T cells, B cells or proliferating bone marrow cells. Further-
more, 6 doses of Bz-423 significantly decreased mortality in several
models of GVHD (B6/F1: 60% vs. 0%, d 21, p \ 0.03; Balb/
c/B6: 100% vs. 40%, d 60, p \ 0.02; C3H.SW/B6: 71% vs.
25%, d 80, p\ 0.02) and significantly reduced GVHD-associated
pathology in the liver and intestine. Importantly, Bz-423 treatment
did not impair immunologic reconstitution or donor engraftment.
The beneficial effects of Bz-423 were due to its ability to induce
apoptosis, as treatment with a pan-caspase inhibitor abrogated any
survival benefit. We conclude that alloreactive donor T cells have
an abnormalmetabolic phenotype evidenced by increasedOXPHOS
and depleted antioxidants that can be exploited for selective
immunotherapy of GVHD without inhibiting hematopoeitic
reconstitution.Table 1.
OXPHOS Glycolysis
(nMoles
O2/(min*10
6
cells))(nMoles
lactate/
(min*106 cells))Pyruvate
(pMoles/mg
protein)Proliferation
IndexUnstimulated T 0.20 (0.03) 0.07 (0.02) 10.4 (3.0) -
Alloreactive
donor T
0.48 (0.05)* 0.53 (0.07) 0.2 (0.1)* 3.5 (0.04)*Proliferating
Bone
Marrow0.23 (0.05) 0.90 (0.11)* 8.5 (2.3) 1.7 (0.07)*p<0.053
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To develop a clinically relevant strategy for gene therapy of in-
herited bleeding disorders, we investigated if Factor VIII (FVIII)
could be stored in platelets derived from lentivirus-transduced he-
matopoietic stem cells of dogs withHemophilia A. This should allow
the release of FVIII from activated platelets as a hemostatic response
to a severe bleeding episode. cG-CSF/cSCF mobilized peripheral
blood stem cells (PBSC) were immuno-selected for CD34 from an
apheresis product, transduced with a lentivirus encoding the plate-
let-specific integrin aIIb gene promoter driving expression of human
FVIII. The PBSC (2 x 10^6/kg) were autologously transplanted (Tx)
into animals preconditioned with Bulsulfan (5-10 mg/kg i.v.). Three
Tx recipients underwent periodic testing for expression of the FVIII
transgene as well as immune tolerance and phenotypic correction of
HemA. LAMPCR localized the lentivirus in genomicDNA isolated
from leukocytes of each dog. Immunofluorescence confocal micros-
copy detected FVIII in a subset of platelets. Immune electron mi-
croscopy revealed that FVIII was stored in the platelet a-granules.
Chromogenic analysis of the platelets demonstrated that FVIII wasS149
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mU/ml/108 platelets from 20 wks through 2 yrs after PBSC Tx. In
contrast, FVIII:C was not detected within the plasma of these ani-
mals. This result coupled with the use immunomodulation drugs
may help to explain why the dogs remained tolerant of human FVIII
as indicated by our inability to detect inhibitory antibodies to FVIII.
Following successful gene transfer and PBSC engraftment, all ani-
mals showed signs of clinical improvement of Hem A: the 1st Tx re-
cipient had 1 bleed/yr for 2 yrs (vs expected 5/yr), the 2nd dog has not
bled for 20 months following PBSC Tx and the 3rd animal had nobleeding for 10 months post Tx. In addition, the 1st Tx dog showed
recovery from prolonged history of chronic gastrointestinal bleed-
ing. All 3 animals displayed improved whole blood clotting times.
This data is consistent with our previous results demonstrating syn-
thesis, trafficking, storage and release of FVIII from a-granules of
human megakaryoyctes in vitro and platelets of the murine model
for Hem A. The outcome demonstrates a feasible strategy for con-
trolling severe bleeding episodes in patients with Hem A by provid-
ing a locally inducible secretory pool of FVIII in platelets derived
from an autologous Tx of FVIII-transduced PBSC.
